CVS Health said total revenues for the 3 months ended March 31, 2025 increased $6.2 billion, or 7.0%, compared with the prior year, driven by revenue growth across all segments.

1. 01

   CVS Health said total revenues for the 3 months ended March 31, 2025 increased $6.2 billion, or 7.0%, compared with the prior year, driven by revenue growth across all segments.

2. 02

   The company said operating income for Q1 increased $1.1 billion, or 48.6%. It added that the results reflected a $387 million litigation charge related to a jury verdict against Omnicare and a $247 million pre-tax loss on Accountable Care assets during the period.

3. 03

   CVS Health said the medical benefit ratio in its Health Care Benefits segment decreased to 87.3% from 90.4% in the prior year, and adjusted operating income increased $1.3 billion, or 172.3%. The company recorded a $448 million premium deficiency reserve in its individual exchange product line.

4. 04

   The company said cash and cash equivalents as of March 31, 2025 were approximately $10.1 billion, and $1.3 billion of commercial paper was outstanding. CVS Health added that it had no borrowings under its back-up credit facility on that date.

Key figures

Quarter ended March 31, 2025

Revenue

$94.6B

Operating income

$3.4B

Net income

$1.8B

EPS

$1.41

Operating cash flow

$4.6B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.